SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

United States Oncology Diagnostics Market 2016-2017 & 2021 - Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection - Research and Markets
[August 10, 2017]

United States Oncology Diagnostics Market 2016-2017 & 2021 - Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection - Research and Markets


The "US Oncology Diagnostics Market - Forecast to 2021" report has been added to Research and Markets' offering.

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual's cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation, as participants fill the gaps in their technology sets, skill sets, and expertise through the acquisition of specialized laboratories.

Amidst the tests for different cancers, in-vitro diagnostic (IVD) tests measuring multiple biomarkers are gaining favor over single-marker tests, because of their improved specificity and sensitivity. When making coverage decisions for new tests, private and government healthcare plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes.

Important market opportunities that are predicted ith high certainty include the clinical integration of clinical sequencing technologies and active participation in strategic partnerships. The falling cost of targeted next-generation sequencing (NGS) will be extremely cost-competitive, with the current single-mutation tests. Additional advantages ensure that clinical sequencing and Big Data will play a key role in cancer patient management. The purpose of this study is to provide an overview of the key technologies, companies, and competitive dynamics of the cancer diagnostics market in the United States.

The study covers the following cancer types: breast, ovarian, cervical, colorectal, prostate, and lung.

Key Topics Covered:


1. Executive Summary

2. US Oncology Diagnostics Market Overview

3. Overview of Competitors

4. Total Cancer Diagnostics Market

5. Breast Cancer

6. Ovarian Cancer

7. Cervical Cancer

8. Colorectal Cancer

9. Prostate Cancer

10. Lung Cancer

11. Companion Biomarker Opportunities in Drug Development

12. Future Outlook and Emerging Opportunities

13. Appendix

Companies Mentioned

  • Agendia
  • Becton Dickinson
  • Biodesix
  • Cancer Genetics
  • Epigenomics
  • Exact Science
  • Foundation Medicine
  • Genomic Health
  • MDxHealth
  • Metamark Genetics
  • Myriad Genetics
  • nanoString Technologies
  • Provista Diagnostics
  • Rosetta Genomics

For more information about this report visit https://www.researchandmarkets.com/research/vkgjv9/us_oncology


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy